China Biologic Products Holdings, Inc. (CBPO)
| Market Cap | 4.57B |
| Revenue (ttm) | 514.40M |
| Net Income (ttm) | 141.06M |
| Shares Out | 38.79M |
| EPS (ttm) | 3.57 |
| PE Ratio | 33.06 |
| Forward PE | 21.19 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $118.00 |
| Previous Close | $117.85 |
| Change ($) | 0.15 |
| Change (%) | 0.13% |
| Day's Open | 117.86 |
| Day's Range | 117.53 - 118.40 |
| Day's Volume | 194,386 |
| 52-Week Range | 97.91 - 120.01 |
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call Transcript
BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical comp...
It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript
The following companies have grown their earnings per share over a five-year period.
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call Transcript
These stocks slot into any portfolio and will pack a special punch.
Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2019 Results - Earnings Call Transcript
As of September 18, 2019, the company received a non-binding proposal to be acquired for $120/share.
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2019 Results - Earnings Call Transcript
According to the GuruFocus All-In-One Screener, the following companies have grown their book value per share over the past decade.
China Biologic Products Holdings, Inc. (CBPO) Management on Q1 2019 Results - Earnings Call Transcript
China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for th...
China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The fastest growing fast-casual franchise as restaurant spending surges
Jersey Mike's CEO Peter Cancro discusses his company's expansion as restaurant spending in the U.S. has surged in the last three months, to the most on record.
About CBPO
China Biologic Products Holdings engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provi... [Read more...]
| Industry Biotechnology | |
| CEO David Gao | Employees 2,246 |
| Stock Exchange NASDAQ | Ticker Symbol CBPO |
Financial Performance
In 2019, CBPO's revenue was $503.74 million, an increase of 7.90% compared to the previous year's $466.88 million. Earnings were $138.81 million, an increase of 8.40%.
Analyst Forecasts
According to 2 analysts, the average rating for CBPO stock is "Hold." The 12-month stock price forecast is 102.78, which is a decrease of -12.90% from the latest price.